2020 Rare Disease Day
February 28, 2020 9:30 AM - 2:00 PM
Omni Parker House, 60 School St Boston MA 02108
Add to Calendar
2/28/2020 9:30:00 AM
2/28/2020 2:00:00 PM
2020 Rare Disease Day
The last day of February has been designated as Rare Disease Day in Massachusetts to call attention to the public health issues associated with rare diseases, which affect nearly 30 million Americans and countless others around the world. The event recognizes Rare Disease Day and the research being done in Massachusetts to treat and cure rare disease.
This year’s agenda will feature two panels: one from the patient perspective on how they’ve turned their diagnoses into their life’s work, finding empowerment through advocacy and action; and one from the industry’s perspective on how researchers and providers are not only tailoring a therapy for a specific patient but also the entire patient experience, and how this outlook has shaped their careers.
Alone we are rare, together we are strong.
To inquire about sponsorship opportunities, contact Laura Rudberg.
Omni Parker House, 60 School St Boston MA 02108
This year’s agenda will feature two panels: one from the patient perspective on how they’ve turned their diagnoses into their life’s work, finding empowerment through advocacy and action; and one from the industry’s perspective on how researchers and providers are not only tailoring a therapy for a specific patient but also the entire patient experience, and how this outlook has shaped their careers.
Alone we are rare, together we are strong.
To inquire about sponsorship opportunities, contact Laura Rudberg.
Omni Parker House, 60 School St Boston MA 02108
President and CEO, Fulcrum Therapeutics
Robert J. Gould joined Fulcrum as president and CEO at the time of the company’s launch in 2016, bringing over 30 years of experience to the role. Previously, he served as president and CEO of Epizyme from 2010 to 2015. Prior to joining Epizyme, Robert served as director of novel therapeutics at Broad Institute of MIT and Harvard from 2006 to 2010. Robert spent 23 years at Merck where he held a variety of leadership positions, culminating in the role of vice president, licensing and external research. During his time at Merck, Robert was instrumental in advancing more than 20 compounds from discovery into clinical development in multiple therapeutic areas. Robert received a bachelor’s from Spring Arbor University and a Ph.D. from the University of Iowa and completed postdoctoral studies at Johns Hopkins University.
Brought to you by
Brought to you by